Choosing between glass and plastic packaging for cannabis concentrates is a strategic decision with downstream consequences for product integrity, compliance, consumer perception, margins, and brand positioning. This article compares the two materials across five dimensions and offers a decision framework for operators to match packaging to product type, brand strategy, and operational scale.

Why packaging choice is a strategic decision

Cannabis concentrates are one of the fastest-growing categories in the legal market. The U.S. cannabis industry is projected to grow at a 12.2% compound annual rate through 2030, with concentrates capturing an increasing share as consumer preferences shift toward potency, terpene-rich profiles, and premium product experiences. Packaging has not always kept pace with the nuances of what concentrates actually need.

The choice between glass and plastic isn’t just a procurement decision. It affects how well the product holds up on the shelf, whether the brand meets compliance requirements that vary state by state, how consumers perceive the product at the point of sale, what it costs to ship and handle, and how the brand stands on sustainability. There’s no universally right answer. The right material depends on the product type, the brand position, the regulatory environment, and the scale of the operation.

What follows is a comparison across five dimensions, along with a decision framework operators can use to match packaging to strategy.

Preservation and product integrity

The first job of concentrate packaging is protecting the product from degradation. Cannabinoids and terpenes are sensitive to light, oxygen, heat, and time, and the packaging that surrounds them is often the difference between a product that delivers on its label and one that doesn’t.

Cannabis cultivation is, at its core, a controlled environment business, and air quality remains one of the most consistently underestimated variables in the operation. Contaminated batches, worker health complaints, and odor violations affecting neighboring communities can all be traced back to air-handling decisions made early in facility design or overlooked during scale-up. Mandatory testing gets attention, but prevention rarely does. The following five mistakes are showing up more and more across licensed facilities today, and each one carries the potential for high costs, both in revenue and to the brand.

Calling MERV 8 Filters Good Enough

Traditional MERV 8, the same ones that you might install in your home HVAC system, captures larger dust particles but allows bacteria, mold spores, and fine particulates to pass through freely. MERV 13, by comparison, which is qualified for hospitals, data centers, and schools, captures particles down to 0.3 microns, including the bacterial range that MERV 8 consistently misses.

During the COVID-19 pandemic, the CDC and ASHRAE aligned on MERV 13 as the baseline standard for critical air-quality environments, a threshold that cannabis cultivation facilities clearly meet given their biological sensitivity. Most modern HVAC systems are engineered to handle MERV 13 without significant airflow or performance penalties. The upgrade cost is modest, but a single failed batch from microbial contamination is not.

Most cannabis operators have a banking problem. For many, that means limited access to financial services, forcing the business to operate largely in cash and be unable to use the standard banking rails every other industry takes for granted. The banking conversation in this industry almost always stops at access. Can the business get an account? Can it keep one? 

Those are real questions, and the answer to both is yes, but they are the wrong ones to stop at. The conversation should continue into how the business is actually functioning within whatever banking access it has, and whether that access is doing the work the business needs. Having some banking is not the same as having a dependable financial infrastructure, and the gap between them does not stay confined to the finance department. It bleeds into operations, labor, vendor relationships, and growth capacity in ways most operators have never stopped to calculate. 

Every margin leak described in the following sections traces back to a banking infrastructure failure, even though none of them are ever labeled that way in a report. Courier costs, absorbed labor hours, vendor friction, untracked losses- these get filed under operations, staffing, or shrinkage. The banking infrastructure that produced them is never identified as the source, and the margin problem remains invisible because no one is looking for it in the right place.

The Costs You Can See

The visible margin hits are straightforward. Cash-heavy operations mean armored transport, on-site storage, and security overhead that eats into the bottom line before the day starts. Because cannabis businesses are largely locked out of standard card processing networks, payment acceptance gets pieced together across alternative solutions that were never designed to work together, creating fragmentation that requires manual reconciliation to function at all. Finance teams spend hours every week manually assembling a cash picture that a business with reliable banking would simply have.

Legalization has been framed as a turning point for cannabis safety, transparency, and adoption for years, but now, over a decade since recreational cannabis sales began, American consumers are taking a closer look and asking tougher questions about whether the industry is living up to that standard. 

What’s becoming clear is this: consumers are ready for a different kind of cannabis industry, one that prioritizes transparency, consistency, and clean products over just high THC percentages. 

A Clear Shift in Consumer Expectations

New consumer data from Royal Queen Seeds, conducted with The Harris Poll, points to a meaningful shift in expectations and needs. Nearly three in four cannabis consumers (72%) say they are concerned about pesticides in their cannabis. That’s a significant jump from previous years, and it reflects a broader shift in how people think about engaging with the plant.

Consumers are becoming more aware of how cannabis is produced and have a rising expectation that the industry should meet the same safety standards they demand from other products. 

Across industries, consumers are asking more questions about sourcing, ingredients, and production practices. They are more informed, more curious, and less willing to take product claims at face value. While this shift for transparency is not unique to cannabis, it should be a wake-up call for brands and operators who have created a THC potency-first business model, and that the industry, despite its regulatory structure, is not exempt from scrutiny about cleanliness.

As U.S. cannabis rescheduling moves forward and export opportunities to the European Union become available, a new certification tool to help producers prove their products meet EU standards and fight back against supply chain fraud is now available.

CSQ (Cannabis Safety & Quality), the first ANAB-accredited cannabis and hemp safety and quality certification program, announced this week the publication of its new EU GMP Addendum, kicking off a public comment period that runs through June 1, 2026. The addendum is designed to help cannabinoid producers worldwide demonstrate compliance with EudraLex Volume 4, Parts 1 & 2, and Annex 7 — the EU’s Good Manufacturing Practice (GMP) regulatory framework for medicinal herbal products.

What the Addendum Does — and Doesn’t Do

The EU GMP Addendum is not a standalone regulatory certification. Rather, it functions as a third-party validation layered on top of a producer’s existing certification issued by a recognized Competent Authority. It gives producers a documented paper trail of compliance that can be presented to potential EU buyers — a critical validation as more North American operators eye the European medical cannabis market.

The tool is also specifically aimed at curbing what CSQ calls “greenwashing” in the cannabis supply chain, a practice where imported products are falsely relabeled as EU GMP-certified before being sold across Europe.

“When a pharmacist in Europe sells a medical cannabinoid product to a patient, they shouldn’t have to question whether or not that product is safe, or if GMPs were followed, they should know without a doubt,” said Darwin Millard, CSQ’s Technical Director.

The U.S. cannabis industry generated more than $30 billion in regulated sales in 2025, yet profitability has become harder to predict. According to a recent national index report by Cannabis Benchmarks, wholesale pricing remains volatile, recently fluctuating between approximately $987 and $1,007 per pound.

In an environment where pricing moves faster than cost structures adapt, profitability is no longer driven by yield alone. It is driven by cost visibility.

Yet many operators still cannot confidently answer a simple question:

What does it truly cost to produce this batch?

Cannabis Is a Batch Manufacturing Business

Every cannabis product, from flower to edibles to pre-rolls, is produced in batches.

As cannabis becomes a globally traded medical commodity, cGMP compliance is reshaping how it is grown, handled, and transported. For operators working with imported biomass, controlling contamination and ensuring consistency across supply chains has become a defining challenge. That challenge was a central focus at the International Cannabis Business Conference in Berlin, where a panel on Good Manufacturing Practices (GMP) examined how operators can meet the European Union’s stringent standards for medical cannabis.

Moderated by Constant Ma, CEO & President of Cannactions Consulting Ltd., the session brought together cultivators, scientists, and technology providers to discuss contamination risk from cultivation through post-harvest processing and packaging.

Unlike many agricultural commodities, cannabis presents a distinct compliance challenge. It is a biological product, inherently variable from batch to batch, and highly susceptible to microbial contamination. In medical markets, particularly in Europe, variability must be tightly controlled.

“All of this is super important because with GMP, we have to make sure that our products are consistent at all times,” Ma said. “And we also have to make sure that it’s safe for the patients that are using it.”

Where Contamination Risk Begins

Panelists emphasized that contamination risk does not begin in processing. It starts in cultivation and carries through every stage of production.

Picture the moment a cannabis company’s compliance team gets copied on an email from a banking partner’s risk officer. The subject line says “Questions re: public materials.” Attached is a spreadsheet. On one side, language from the company’s Florida medical dispensary website. On the other, language from the California recreational site, the New Jersey acquisition press release, and a quote from the CEO’s interview in a trade publication eight months ago. The risk officer wants to understand how all of it reflects the same company, because from where she’s sitting, it doesn’t. 

This is not a hypothetical. It is a conversation that is becoming more frequent as financial institutions become more sophisticated in how they evaluate cannabis operators.

Inconsistent messaging across states is not a brand problem. It is an operational risk that has been misclassified, and companies that treat it as a marketing issue tend to find out the hard way that they have compliance exposure.

What Regulators and Banks Are Actually Looking At

A state regulator reviewing a multi-state operator and a financial institution conducting due diligence are doing the same thing, even if they don’t describe it that way. Both are trying to determine whether the organization they’re looking at is actually in control of itself, its operations, its decisions, and its story.

Take a company positioning itself as a premium medical operator in Florida, a value-driven recreational brand in California, and a community dispensary in New Jersey. From the inside, that probably reads as market awareness. From a regulator’s desk or a bank’s credit committee, it reads as an organization that hasn’t decided what it actually is. Localization is a legitimate strategy. Contradiction isn’t.

Cannabis packaging decisions have downstream consequences for compliance, operations, customer perception, and margins. This article offers a practical framework for evaluating packaging suppliers across five dimensions: compliance, product quality, operational fit, customization, and partnership reliability. It closes with a pre-commitment checklist that operators can use before signing any supplier agreement.

Cannabis packaging is no longer a purchasing decision. It’s a strategic one. The wrong supplier can compromise compliance, disrupt operations, damage brand perception, and erode margins in ways that far exceed any line-item savings on the invoice. And once a brand is locked in, switching suppliers mid-stride tends to be both expensive and operationally painful.

The cannabis packaging market is also crowded and uneven. Quality varies widely, regulatory requirements are shifting state by state, and the pace of change has accelerated. The Texas Department of State Health Services (DSHS) rolled out sweeping new packaging rules for consumable hemp products on March 31, 2026, giving businesses roughly 20 days of notice before the requirements took effect. For operators, that kind of timeline is a reminder that supplier selection isn’t just about today’s products. It’s about whether a supplier can keep up with what’s coming.

The framework below covers five evaluation criteria and a pre-commitment checklist. Together, they’re designed to help operators separate suppliers who can sustain a long-term relationship from those who will create friction at every turn.

Start with compliance, not price

Compliance has to be the first filter, not an afterthought. A supplier who can’t speak fluently to state-specific rules or can’t point to how their products meet current requirements is a supplier who will cost more than they save.

Driven by innovation and convenience, pre-roll sales in 2025 not only had the strongest growth of any major category, topping $3.6 billion in sales and moving 383 million units, but supplanted flower as the most units sold for the first time in the industry’s history, according to a new report from Custom Cones USA.

It’s the fifth consecutive year that pre-rolls have outperformed the industry as a whole, growing revenues 9.8% year-over-year, well ahead of the 1.5% growth rate of the entire sector. On top of that, unit sales grew 18.6%, helping lead the category to a 15.9% market share.

In total, pre-rolls have seen by far the largest growth of any category over the past five years, driving growth for the entire industry, despite having the lowest average price point of any major category at just $9.18.

“Pre-rolls are no longer an afterthought,” said Harrison Bard, CEO of Custom Cones USA. “What started as a trim byproduct, pre-rolls have matured into a highly competitive, innovation-driven category where brands are winning through quality, scale, and smart branding.”

Drawing on point-of-sale data from 15 states collected by cannabis analytics firm Headset, as well as a survey of pre-roll manufacturers from around the country, the State of the Pre-Roll Market 2026 report shines a spotlight on this growing and important category, revealing what pre-rolls are selling, how they are being sold, and who is buying them.

As federal policymakers move toward restricting hemp-derived cannabinoid products, a new state-level effort in Colorado is taking the opposite approach by moving to integrate low-dose THC beverages into mainstream hospitality.

A coalition led by Colorado-based attorney Brian Vicente, partner at Vicente LLP, has formed the Colorado THC Beverage Coalition and introduced legislation that would allow hemp-derived THC beverages—up to 10 milligrams per serving—to be sold and consumed in bars, restaurants, and event venues.

If successful, the bill would position Colorado alongside states like Minnesota and Tennessee, which have emerged as early leaders in normalizing hemp-derived THC beverages in social, alcohol-adjacent settings.

A Three-Tier System for THC?

At the core of the Colorado proposal is to treat THC beverages more like alcohol.

As the U.S. hemp industry braces for potential federal disruption later this year, a new bipartisan bill aims to give states a way to maintain control over intoxicating hemp products and potentially keep the category alive.

Sens. Rand Paul (R-KY), Amy Klobuchar (D-MN), and Joni Ernst (R-IA) have introduced the Hemp Safety Enforcement Act, legislation that would allow states and tribal territories to opt out of an anticipated federal ban on intoxicating hemp-derived cannabinoid products. Instead, states could regulate these products under their own frameworks.

The bill arrives at a critical moment for the hemp sector. Federal provisions expected to take effect in November 2026—widely interpreted as banning hemp-derived cannabinoid products exceeding the 0.3% delta-9 THC threshold—have created significant uncertainty across the supply chain. Industry stakeholders warn that, without a legislative fix, the rule could effectively dismantle much of the hemp-derived consumer packaged goods (CPG) market, including fast-growing categories like delta-8 THC beverages, edibles and other ingestibles.

Originally legalized under the Agriculture Improvement Act of 2018, hemp and its derivatives have since evolved into a multi-billion-dollar market. However, the lack of clear federal guardrails has resulted in a fragmented, state-by-state regulatory patchwork. Some states have embraced hemp-derived cannabinoids, while others have moved to restrict or ban them entirely.

Proponents of the Hemp Safety Enforcement Act argue that a state-led approach offers a more practical path forward—preserving existing markets while enabling oversight tailored to local public health and safety priorities. The legislation would also support compliant interstate commerce between states that choose to regulate, rather than prohibit, these products.

For years, the cannabis industry operated in an environment where expansion was the primary signal of success, and investors were excited to get involved. New markets opened, and rapid growth often took priority over efficiency. Companies could move quickly and sort out the details later, trusting that scale would eventually smooth things out.

That environment no longer exists, and in most ways, growth is now more challenging. Margins are tighter, investors are more selective, and competition has intensified. Those changes are forcing a closer look at how businesses actually perform beneath the surface to survive. Growing sales is crucial, but sustaining profitability and managing working capital over the long haul are essential to success. 

This shift tends to start with cost visibility. To survive and thrive, cannabis operators must understand their product unit economics and the variables that influence them. In a compressed market, small inefficiencies have a way of compounding. A slight increase in input costs or a mismatch in pricing strategy can quietly erode performance over the course of a quarter.

None of this is theoretical. It shows up in day-to-day decisions around production, sales, marketing, and where to invest resources.

Growth strategy is evolving alongside that reality. Expansion into new markets still carries long-term value, but it is harder to justify without the infrastructure to support it. Entering a new market introduces layers of operational complexity, and success depends on more than securing shelf space. Distribution, retail relationships, and localized execution all factor into whether a brand actually thrives in a new setting.

In 2024, Colorado state officials announced a recall affecting 172 stores across the state. Batches of flower and pre-rolled joints from one grower exceeded mold and yeast limits. The losses were immense, including for companies that thought the money they were paying each year to insurance companies for premiums would provide, only to discover that coverage wasn’t there when it mattered most.

This is not an isolated story. Cannabis operators across the country pay high premiums for policies riddled with exclusions, resulting in enormous uninsured exposure to areas including product recall, regulatory action, business interruption, cyber liability, and directors and officers coverage. Section 280E makes every uninsured loss even more painful, with effective tax rates that can exceed 60 percent of gross income. The commercial insurance market has failed this industry structurally. Some operators are looking at captive insurance as a structural solution.

What Is a Captive Insurance Company?

A captive is a licensed insurance company that your business owns. Rather than paying premiums to a carrier that keeps the underwriting profit, the promise of a captive is that owners can accumulate reserves, keep the insurance company’s profit, and write policies covering risks that commercial markets refuse to underwrite. As such, it is worth looking at the pros and cons of forming a captive.

The Pros

Coverage for gaps no commercial carrier will fill. Control over your risk program, on your terms, based on your coverage and philosophy. Financial upside: underwriting profit stays in your business, not your carrier’s. Stability against volatile premium markets. Risk management discipline that improves your operations over time. And a powerful signal to investors and acquirers that your business is built with institutional-grade infrastructure, which is a meaningful advantage in capital raises and exit valuations.

A cannabis biopharma company is seeking to join the federal lawsuit challenging the Centers for Medicare & Medicaid Services’ (CMS) new hemp and CBD pilot program, adding a pharmaceutical voice to a government-sanctioned program allowing untested and unregulated hemp products into the marketplace.

MMJ International Holdings and its subsidiaries, MMJ BioPharma Labs and MMJ BioPharma Cultivation, have moved to join the lawsuit filed by Smart Approaches to Marijuana (SAM) and other plaintiffs against CMS and federal health officials.

The move comes after the court denied the plaintiffs’ emergency request for a temporary restraining order on March 31, allowing the program to launch while the litigation continues. The court is scheduled to hold a preliminary injunction hearing on April 20.

SAM and its co-plaintiffs filed suit on March 30 in the U.S. District Court for the District of Columbia seeking to block CMS’s new Substance Access Beneficiary Engagement Incentive, or BEI. The optional Innovation Center program allows participating organizations to discuss eligible hemp-derived products with Medicare beneficiaries and, under the model’s rules, furnish them for symptom management.

CMS has argued that the BEI is not a broad Medicare coverage expansion and does not directly reimburse hemp or CBD products in the same way as a traditional Medicare benefit.

All roads in cannabis retail lead back to inventory.

Retail cannabis operators across the country are being squeezed by razor-thin margins, declining cash flow, and a growing inability to pay vendors on time. The culprit is often not weak sales or lack of demand. It is mismanaged inventory.

Inventory is the foundation on which the entire business is built. It is the single biggest driver of cash flow, profitability, and retail performance. Yet many retailers are still carrying too much product, reordering too late or too early, and failing to connect inventory decisions to merchandising, promotions, sell-through, and actual consumer demand. Brands feel the impact too. They cannot accurately forecast production, plan manufacturing schedules, or maintain healthy warehouse levels when retailers are not managing inventory effectively.

Excess inventory locks up cash, slows vendor payments, compresses margins, and creates pressure to discount. Too little inventory creates out-of-stocks, lost sales, frustrated customers, and strained brand relationships. In either scenario, poor inventory management undermines every other part of the business.

Many cannabis retailers are far exceeding the 30-day product turnover goal needed to keep cash flowing and inventory fresh. Some operators are sitting on more than $150,000 in overstock every month, cash that could otherwise be used to pay vendors, invest in marketing, open new locations, or strengthen operations.

From cultivation to retail, businesses are digging deep to tighten operations and increase margins as the only way to endure another grueling year in cannabis without federal support.

A common sales pitch these days centers on cost-saving systems and operational efficiency. The industry has shifted from “how fast can we grow?” to “how do we survive profitably?” There is little tolerance left for inefficiency.

A glance at the agenda for the upcoming MJ Unpacked show in Atlantic City, kicking off May 5, offers insights into the industry’s current challenges as we move through 2026. According to co-founder George Jage, the programming is shaped by input from committees across retail, brands, and cultivation, made up of operators who meet regularly to share pain points and what they are seeing on the ground.

“There’s no higher level of learning than peer-to-peer learning, and understanding the biggest pain points,” says Jage. “We take that information and design panels around the challenges and solutions operators are actually dealing with.”

Here is what I gleaned from this year’s agenda and where the industry is focusing. If the industry is going to stabilize, tight execution at every phase will matter.

For many cannabis founders, the exit problem is not finding the right buyer. It is that there are barely any buyers at all. The field is narrow, capital is tight, and the strategic buyers that do exist are rarely showing up with clean cash offers. More often, founders are being asked to accept low valuations, seller paper, stock in the buyer, or some other compromise that falls short of a real exit.

That leaves owners in a bad spot. They can sell on terms they do not like and watch the company they built get absorbed into a larger platform. Or they can keep running the business and hope the market improves. Neither is a strong answer for a founder who wants liquidity now.

For years, the industry has told itself a familiar story. Survive the chaos, build something real, wait for institutional capital, and eventually a good buyer will show up. It is a nice story. It just has not been true for most operators.

Cannabis does not have a deep buyer universe. 

Most private equity firms have stayed away from plant-touching companies because there is no clear exit path. Most large strategic buyers have their own capital constraints, which means they buy selectively and often on terms that shift risk back to the seller. At the same time, 280E has drained cash from otherwise solid businesses, making it harder for founders to wait around for a market that may or may not improve.

That is why so many owners have been stuck in the same position for years: they have built valuable businesses, but when they want liquidity, the options are limited, and the terms are often weak. “Hold on, and the buyers will come” is not much of a plan.